Catecholamines

Kyowa Kirin Announces NOURIANZ™ (Istradefylline) Now Available in the U.S. for Treatment of Parkinson’s Disease “Off” Episodes

Monday, October 14, 2019 - 11:47pm

Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.

Key Points: 
  • Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • To help patients with questions about access to NOURIANZ, Kyowa Kirin offers the Kyowa Kirin Cares program.
  • NOURIANZ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Neuroscientist awarded $2.9M NIH grant to improve Parkinson's disease treatment

Wednesday, September 25, 2019 - 8:03pm

Parkinson's disease is the second most common neurodegenerative disease in the United States.

Key Points: 
  • Parkinson's disease is the second most common neurodegenerative disease in the United States.
  • Levodopa is the drug most frequently used to manage the symptoms of Parkinson's disease.
  • This potentially disabling side effect poses a major challenge in the long-term management of patients living with Parkinson's disease.
  • The NIH grant supports his study titled Neurovascular Effects of Dopamine Replacement Therapy in Parkinson's Disease.

Acorda Therapeutics to Present at the 2019 Cantor Healthcare Conference

Wednesday, September 25, 2019 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4 at 11:15AM ET.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4 at 11:15AM ET.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Cerevel Therapeutics to Present Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease

Thursday, September 19, 2019 - 9:58pm

Cerevel Therapeutics , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present new data from a Phase 2 clinical trial evaluating tavapadon (formerly PF-06649751) in patients with early-stage Parkinsons disease at the 2019 International Congress of Parkinsons Disease and Movement Disorders , taking place from September 22-26 in Nice, France.

Key Points: 
  • Cerevel Therapeutics , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present new data from a Phase 2 clinical trial evaluating tavapadon (formerly PF-06649751) in patients with early-stage Parkinsons disease at the 2019 International Congress of Parkinsons Disease and Movement Disorders , taking place from September 22-26 in Nice, France.
  • Tavapadon is a novel, investigational, orally-administered, selective partial agonist of the dopamine D1 and D5 receptors.
  • Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinsons, epilepsy, schizophrenia and addiction.
  • Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Acorda to Present Data at the International Congress of Parkinson’s Disease and Movement Disorders

Wednesday, September 18, 2019 - 12:00pm

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data at the International Congress of Parkinsons Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data at the International Congress of Parkinsons Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France.
  • Fox Foundation Industry Advisory Board and contributed to the design of and provided funding for the Financial and Social Impact of Parkinsons Disease Survey.
  • Results of the survey were also presented at the 5th World Parkinson Congress in June 2019.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.

Kyowa Kirin Announces FDA Approval of NOURIANZ™ (istradefylline) for Use in Parkinson’s Disease

Wednesday, August 28, 2019 - 2:34pm

Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZ (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing OFF episodes.

Key Points: 
  • Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZ (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing OFF episodes.
  • We are proud that NOURIANZ is now ready to help adult patients with Parkinsons disease in the US, said Tomohiro Sudo, Head of Global Product Management Office of Kyowa Kirin.
  • We are grateful for the FDA approval and for the many dedicated scientists and patients whose participation in our research programs has resulted in a new treatment option for Parkinson's disease.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Acorda Receives Positive CHMP Opinion for INBRIJA™ (levodopa inhalation powder)

Friday, July 26, 2019 - 1:30pm

The European Commission (EC) will now consider the CHMP positive opinion in its decision of whether to grant marketing authorization for INBRIJA in Europe; the final EC decision is expected in the coming months.

Key Points: 
  • The European Commission (EC) will now consider the CHMP positive opinion in its decision of whether to grant marketing authorization for INBRIJA in Europe; the final EC decision is expected in the coming months.
  • Acorda is currently evaluating partnering opportunities to commercialize INBRIJA in Europe.
  • The positive CHMP decision is based on a clinical program for INBRIJA that included approximately 900 people with Parkinsons on a levodopa/dopa-decarboxylase inhibitor regimen experiencing OFF periods.
  • INBRIJA utilizes Acordas innovative ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation.

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease

Wednesday, July 10, 2019 - 9:10pm

With opicapone, we aim to prolong the benefits of levodopa by providing a new treatment option to patients with Parkinson's disease in the U.S.," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.

Key Points: 
  • With opicapone, we aim to prolong the benefits of levodopa by providing a new treatment option to patients with Parkinson's disease in the U.S.," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.
  • We look forward to working with the FDA to bring this new treatment option to patients coping with this debilitating disorder."
  • Neurocrine Biosciences in-licensed opicapone from BIAL in 2017 and has exclusive development and commercialization rights in the U.S. and Canada.
  • Opicapone, an investigational treatment for Parkinson's disease in the U.S., is a novel, once-daily, selective catechol-O-methyltransferase (COMT) inhibitor.

Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders

Tuesday, June 25, 2019 - 12:00pm

JERUSALEM, June 25, 2019 /PRNewswire/ ---Intec Pharma Ltd.(NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier Phase 2 clinical study of the Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients were published in the peer-reviewed journal, Parkinsonism and Related Disorders.

Key Points: 
  • JERUSALEM, June 25, 2019 /PRNewswire/ ---Intec Pharma Ltd.(NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier Phase 2 clinical study of the Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients were published in the peer-reviewed journal, Parkinsonism and Related Disorders.
  • The article presents results from cohorts 1-4 out of the 6 cohorts of PD patients who participated in the study.
  • Intec Pharma routinely posts information that may be important to investors in the Investor Relations section of its website.
  • Modi, Clinical pharmacokinetics of IPX066: evaluation of dose proportionality and effect of food in healthy volunteers, Clin.

Acorda Therapeutics to Present at Jefferies 2019 Healthcare Conference

Thursday, May 23, 2019 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in patients with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.